Skip to content
MedsAcross

Medicine

Dactinomycin 0.5 mg/mL powder for injection

Dactinomycin · Intravenous
Available on requestPrescription onlyUS FDAGeneric name

Dactinomycin 0.5 mg/mL powder for injection is a generic prescription medicine for intravenous use, made by 3 labelers, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.

Availability

Available on request

Export supply from India to licensed buyers

Typical lead time

On request

Counted from payment and complete documents

Shipping

Ambient

Store at 20º to 25ºC (68º to 77ºF),. Protect from light and humidity.

Key facts

Active ingredient (INN)
Dactinomycin
Brand
Sold under the generic name
Strength
0.5 mg/mL
Dosage form
Powder for injection
Route
Intravenous
Packs
1 vial and 1 more
Manufacturers
EugiaIndiaMeitheal PharmaceuticalsXGen Pharmaceuticals DJB
Origin register
US FDA, United States
Storage
Store at 20º to 25ºC (68º to 77ºF),. Protect from light and humidity.
Cold chain
Not required on record
Prescription status
Prescription only
Controlled substance
Not recorded as controlled
ATC code
L01DA01 Dactinomycin
HS code (indicative)
3004.90Indicative only. Your customs broker confirms the final tariff code.
Marketing category
marketed
Marketed since
31 July 2019
Identifiers
RxCUI 239179DailyMed set ID 5da55538-2602-4704-a9da-603c9f7ff7dc, 2aaca42a-3b79-4151-a727-83253556a540, efe03d73-eb11-45ff-a3cb-09a540ed352f +1NDC 55150-928, 71288-129, 39822-2100 +1Application ANDA203385, ANDA213463, ANDA203999

Record updated 12 November 2026

Documents available

Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.

No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.

Packs

Packs from every labeler of this generic presentation.

PackCodeLabelerMarketed since
1 vial, single-dose in 1 carton / 1 mL in 1 vial, single-dose55150-431-01EugiaIndia15 March 2021
1 vial, single-dose in 1 carton / 1 mL in 1 vial, single-dose55150-928-02EugiaIndia15 March 2021
1 vial, single-dose in 1 carton / 1 mL in 1 vial, single-dose71288-129-02Meitheal Pharmaceuticals13 November 2020
1 vial, single-dose in 1 carton / 1 mL in 1 vial, single-dose39822-2100-2XGen Pharmaceuticals DJB31 July 2019

Status by register

Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.

RegisterStatusSource
US FDAListed, marketedSource record for this pageChecked 12 November 2026
US FDAFirst approved 10 December 1964Drugs@FDA
EU (EMA)Not recorded—
India (CDSCO)Not yet confirmed against CDSCO approval lists—
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Import route

Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.

Import guides are available for 25 countries. Pick one to see its route summary.

BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides

Other strengths and forms of Dactinomycin

Clinical summary

Dactinomycin is an actinomycin indicated for the treatment of adult and pediatric patients with Wilms tumor, as part of a multi-phase, combination chemotherapy regimen, among other approved uses. MedsAcross supplies Dactinomycin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Read about Dactinomycin

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

Data sources

Need Dactinomycin 0.5 mg/mL powder for injection for your hospital or patient?

Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.